London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series B cash.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biotechnology company Purespring Therapeutics has ...

Cross-sectional images of IgA nephropathy murine kidneys. Purespring gene therapy significantly improves kidney morphology and reduces the areas of scarring and fibrosis stained in blue. Results ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to take a gene therapy for a kidney disease into the clinic. The money ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment ...

Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) London – 9 ...

Purespring is based on technology from Moin Saleem, a professor of pediatric renal medicine at the University of Bristol. It’s Syncona’s sixth gene therapy company since 2012.

Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome. Science Translational Medicine , 2023; 15 (708) DOI: 10.1126/scitranslmed ...

Ambra Cappelletto, Principal Scientist at Purespring, commented: "Our data demonstrate that targeting podocytes to modulate complement activation is an effective therapeutic strategy, and PS-002 paves ...

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 million in a ...

Results from the study underpin the potential of Purespring’s lead AAV gene therapy programme, PS-002, as an important novel modality to treat IgAN Data support progression towards a Phase I/II ...